Form 4: Immix Biopharma Director Helen Adams Granted 33,000 Stock Options

Immix Biopharma, Inc. Director Helen C. Adams was granted 33,000 stock options with an exercise price of $2.24, vesting over twelve months, as disclosed in a recent SEC Form 4 filing.

Summary

• Helen C. Adams, a Director of Immix Biopharma, Inc. (IMMX), was granted 33,000 stock options on June 20, 2025.
• The exercise price for these options is $2.24 per share.
• These options will vest in twelve equal monthly installments, contingent upon Ms. Adams' continued service on the Board of Directors.
• The options have an expiration date of June 20, 2035.
• Following this transaction, Ms. Adams beneficially owns 174,754 shares of common stock directly and 33,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard practice for aligning management incentives with shareholder value. It reflects ongoing compensation and commitment rather than a significant positive or negative operational event.

Positives

• The grant of stock options to a director aligns the director's interests with shareholder value creation.
• The vesting schedule encourages long-term commitment and continued service from the director.

Future Outlook

NA

Industry Context

This Form 4 filing details a standard equity compensation grant to a director, a common practice across the biopharmaceutical industry to incentivize leadership and align their interests with long-term company performance. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's interests with shareholder value, potentially leading to better long-term performance. It also represents potential future dilution if options are exercised.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The stock options will continue to vest in twelve equal monthly installments following the grant date, subject to Helen C. Adams' continued service on the Board of Directors.

Key Dates

Recommendation

Keywords

Immix Biopharma, IMMX, SEC Form 4, Stock Option Grant, Director Compensation, Beneficial Ownership, Equity Compensation, Biopharma, Helen C. Adams